Jason Chen1, Justine Abella Ross1, Bernard Tegtmeier2, Dongyun Yang3, James I Ito4, John A Zaia5,6, Jana K Dickter4, Ryotaro Nakamura6, Sally Mokhtari7, Jane Kriengkauykiat8, Monzr M Al Malki6, Sanjeet S Dadwal4. 1. Department of Pharmacy, City of Hope, Duarte, California. 2. Department of Quality, Risk and Regulatory Management, City of Hope, Duarte, California. 3. Department of Information Sciences, City of Hope, Duarte, California. 4. Department of Medicine, Division of Infectious Disease, City of Hope, Duarte, California. 5. Center for Gene Therapy, City of Hope, Duarte, California. 6. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California. 7. Department of Clinical Translational Program Development, City of Hope, Duarte, California. 8. Department of Pharmacy, Grady Health, Atlanta, Georgia.
Abstract
BACKGROUND: Ganciclovir (GCV) and foscarnet (FOS) are the most commonly used antivirals for preemptive treatment of cytomegalovirus (CMV) viremia in recipients of allogeneic hematopoietic cell transplantation (alloHCT). The current literature indicates similar efficacy between these agents. Thus, the primary consideration for choice of initial anti-CMV treatment is the safety profile, time period after alloHCT, and concern of myelosuppression or renal dysfunction. METHODS: Herein, we retrospectively reviewed medical records of 124 alloHCT recipients who received GCV or FOS between April 27, 2014, and December 31, 2015, during the first year post-transplant. Healthcare resource use included drug, hospitalization, home health, dialysis, and growth factor costs. RESULTS: Total duration of therapy was longer in the GCV group (37 days vs 28 days, P = .21) but hospitalization days were similar (9 days) in both groups. The total treatment cost was significantly lower in the GCV group ($38 100 vs $59 400, P < .05). CONCLUSION: Preemptive anti-CMV therapy is associated with major healthcare resource costs, which were greater in patients who required FOS than those who were treated with GCV.
BACKGROUND:Ganciclovir (GCV) and foscarnet (FOS) are the most commonly used antivirals for preemptive treatment of cytomegalovirus (CMV) viremia in recipients of allogeneic hematopoietic cell transplantation (alloHCT). The current literature indicates similar efficacy between these agents. Thus, the primary consideration for choice of initial anti-CMV treatment is the safety profile, time period after alloHCT, and concern of myelosuppression or renal dysfunction. METHODS: Herein, we retrospectively reviewed medical records of 124 alloHCT recipients who received GCV or FOS between April 27, 2014, and December 31, 2015, during the first year post-transplant. Healthcare resource use included drug, hospitalization, home health, dialysis, and growth factor costs. RESULTS: Total duration of therapy was longer in the GCV group (37 days vs 28 days, P = .21) but hospitalization days were similar (9 days) in both groups. The total treatment cost was significantly lower in the GCV group ($38 100 vs $59 400, P < .05). CONCLUSION: Preemptive anti-CMV therapy is associated with major healthcare resource costs, which were greater in patients who required FOS than those who were treated with GCV.
Authors: Per Ljungman; Ronald Brand; Jennifer Hoek; Rafael de la Camara; Catherine Cordonnier; Hermann Einsele; Jan Styczynski; Katherine N Ward; Simone Cesaro Journal: Clin Infect Dis Date: 2014-05-20 Impact factor: 9.079
Authors: Lynn El Haddad; Shashank S Ghantoji; Anne K Park; Marjorie V Batista; Jonathan Schelfhout; Jack Hachem; Yadira Lobo; Ying Jiang; Gabriela Rondon; Richard Champlin; Roy F Chemaly Journal: J Med Virol Date: 2019-09-03 Impact factor: 2.327
Authors: Veronique Erard; Katherine A Guthrie; Sachiko Seo; Jeremy Smith; MeeiLi Huang; Jason Chien; Mary E D Flowers; Lawrence Corey; Michael Boeckh Journal: Clin Infect Dis Date: 2015-03-16 Impact factor: 9.079
Authors: Pierre Reusser; Hermann Einsele; John Lee; Liisa Volin; Montserrat Rovira; Dan Engelhard; Jürgen Finke; Catherine Cordonnier; Hartmut Link; Per Ljungman Journal: Blood Date: 2002-02-15 Impact factor: 22.113
Authors: Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah Journal: N Engl J Med Date: 2017-12-06 Impact factor: 91.245
Authors: Francisco M Marty; Julie Bryar; Sarah K Browne; Talya Schwarzberg; Vincent T Ho; Ingrid V Bassett; John Koreth; Edwin P Alyea; Robert J Soiffer; Corey S Cutler; Joseph H Antin; Lindsey R Baden Journal: Blood Date: 2007-03-28 Impact factor: 22.113
Authors: Natasha A Jain; Kit Lu; Sawa Ito; Pawel Muranski; Christopher S Hourigan; Janice Haggerty; Puja D Chokshi; Catalina Ramos; Elena Cho; Lisa Cook; Richard Childs; Minoo Battiwalla; A John Barrett Journal: Cytotherapy Date: 2014-05-13 Impact factor: 5.414